Added to YB: 2025-01-31
Pitch date: 2024-12-31
NVO [bullish]
Novo Nordisk A/S
-41.78%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 86.19
Price Target
N/A
Dividend
3.64%
EV/EBITDA
8.92
P/E
13.70
EV/Sales
4.72
Sector
Pharmaceuticals
Category
growth
ClearBridge Large Cap Growth ESG Strategy New Position: Novo Nordisk
NVO: Danish leader in diabetes/obesity treatments. Bought on dip from trial results. Wegovy lost share to Lilly, but CagriSema to compete better. Attractive valuation given large secular growth in diabesity market. Improved product portfolio and supply position expected.
Read full article (1 min)